Overtreatment in rheumatoid arthritis: are there reasons for concern?
作者信息
Ferreira Ricardo J O, Gossec Laure, da Silva Jose Antonio Pereira
机构信息
Nursing Research, Innovation and Development Centre of Lisbon (CIDNUR), Higher School of Nursing of Lisbon, Lisboa, Portugal
Rheumatology, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal.
出版信息
RMD Open. 2022 Sep;8(2). doi: 10.1136/rmdopen-2022-002212.
Abstract
摘要
相似文献
1
Overtreatment in rheumatoid arthritis: are there reasons for concern?类风湿关节炎的过度治疗：是否值得担忧？
RMD Open. 2022 Sep;8(2). doi: 10.1136/rmdopen-2022-002212.
2
Rheumatoid arthritis: past, present and future approaches to treating the disease.
Int J Rheum Dis. 2017 Apr;20(4):417-419. doi: 10.1111/1756-185X.12823. Epub 2016 Feb 4.
3
Does methotrexate cause interstitial lung disease in rheumatoid arthritis: What is the evidence?甲氨蝶呤会导致类风湿关节炎患者出现间质性肺病吗：证据是什么？
Int J Rheum Dis. 2020 Jun;23(6):713-716. doi: 10.1111/1756-185X.13828.
4
Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.类风湿关节炎患者对阿巴西普的保留率及临床反应：意大利视角
Clin Exp Rheumatol. 2018 Sep-Oct;36(5):935-936. Epub 2018 Mar 21.
5
Systematic Review of Recommendations on the Use of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Cancer: Comment on the Article by Lopez-Olivo et al.
Arthritis Care Res (Hoboken). 2020 Dec;72(12):1828. doi: 10.1002/acr.24453.
6
Association Between the Number of Comorbidities and the Risk of a Serious Infection in Rheumatoid Arthritis Treated by a First Biologic Agent.
J Clin Rheumatol. 2022 Jan 1;28(1):e270-e273. doi: 10.1097/RHU.0000000000001618.
7
Rheumatoid arthritis.类风湿关节炎
Foot Ankle Clin. 2007 Sep;12(3):525-37, vii. doi: 10.1016/j.fcl.2007.04.004.
8
Treatment of severe periodontitis may improve clinical disease activity in otherwise treatment-refractory rheumatoid arthritis patients.重症牙周炎的治疗可能会改善其他方面治疗难治的类风湿性关节炎患者的临床疾病活动情况。
Rheumatology (Oxford). 2020 Jan 1;59(1):243-245. doi: 10.1093/rheumatology/kez287.
9
Association between glucocorticoid discontinuation and the incidence of infection in older adults with rheumatoid arthritis: A retrospective cohort study.
Int J Rheum Dis. 2024 Jan;27(1):e14952. doi: 10.1111/1756-185X.14952. Epub 2023 Nov 2.
10
Lymphoma, rheumatoid arthritis, and TNFalpha antagonists.
Joint Bone Spine. 2010 May;77(3):195-7. doi: 10.1016/j.jbspin.2010.02.002. Epub 2010 Apr 15.
本文引用的文献
1
Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis.使用推导得出的28个关节疾病活动评分患者报告部分（DAS28-P）指数，作为早期类风湿关节炎中对改善病情抗风湿药物治疗反应的鉴别指标。
BMC Rheumatol. 2022 Nov 15;6(1):67. doi: 10.1186/s41927-022-00299-3.
2
Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study.在一项达标治疗研究中，达到与未达到 ACR/EULAR 布尔缓解的类风湿关节炎患者的炎症和生物治疗。
RMD Open. 2022 Jan;8(1). doi: 10.1136/rmdopen-2021-002013.
3
High patient global assessment scores in patients with rheumatoid arthritis otherwise in remission do not reflect subclinical inflammation.类风湿关节炎患者在其他方面处于缓解期时的高患者整体评估评分并不能反映亚临床炎症。
Joint Bone Spine. 2021 Dec;88(6):105242. doi: 10.1016/j.jbspin.2021.105242. Epub 2021 Jun 21.
4
Patient global assessment to define remission in rheumatoid arthritis:quo vadis?用于定义类风湿关节炎缓解的患者整体评估：何去何从？
Ann Rheum Dis. 2021 Mar;80(3):277-279. doi: 10.1136/annrheumdis-2020-218802. Epub 2020 Nov 6.
5
Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients.重新审视排除患者整体评估后使用缓解标准治疗类风湿关节炎：对 5792 名患者的个体荟萃分析。
Ann Rheum Dis. 2021 Mar;80(3):293-303. doi: 10.1136/annrheumdis-2020-217171. Epub 2020 Oct 6.
6
The patient global assessment in RA precludes the majority of patients otherwise in remission to reach this status in clinical practice. Should we continue to ignore this?类风湿关节炎患者的整体评估使得大多数原本处于缓解期的患者在临床实践中无法达到这一状态。我们是否应该继续忽视这一点？
Semin Arthritis Rheum. 2020 Aug;50(4):583-585. doi: 10.1016/j.semarthrit.2020.03.014. Epub 2020 May 19.
7
Severe joint deformity and patient global assessment of disease are associated with discrepancies between sonographic and clinical remission: A cross-sectional study of rheumatoid arthritis patients.严重的关节畸形和患者对疾病的总体评估与超声和临床缓解之间的差异有关：一项对类风湿关节炎患者的横断面研究。
Mod Rheumatol. 2021 Mar;31(2):334-342. doi: 10.1080/14397595.2020.1751922. Epub 2020 May 5.
8
Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).在类风湿关节炎中，达标治疗真的有效吗？一项在日常实践中治疗的患者队列的纵向分析（RA BIODAM）。
Ann Rheum Dis. 2020 Apr;79(4):453-459. doi: 10.1136/annrheumdis-2019-216819. Epub 2020 Feb 24.
9
Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?检测不同的患者总体评估阈值在类风湿关节炎缓解定义中的应用：当前的 ACR/EULAR 二分类标准是否最优？
Ann Rheum Dis. 2020 Apr;79(4):445-452. doi: 10.1136/annrheumdis-2019-216529. Epub 2020 Feb 5.
10
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.EULAR 推荐的类风湿关节炎治疗策略：2019 年更新版（使用合成和生物疾病修正抗风湿药物）
Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22.
Zotero 插件